Jane Street’s NRX Pharmaceuticals NRXP Stock Holding History

Jane Street’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$487K	Buy	119,018 +74,866	+170%	+$247K	﹤0.01%	8088
2026 Q1	$94K	Buy	44,152 +6,087	+16%	+$12.3K	﹤0.01%	10682
2025 Q4	$103K	Sell	38,065 -35,334	-48%	-$94.8K	﹤0.01%	10170
2025 Q3	$242K	Buy	+73,399	New	+$210K	﹤0.01%	9317
2024 Q2	–	Sell	-2,769	Closed	-$13.1K	–	9935
2024 Q1	$13.1K	Buy	+2,769	New	+$12.8K	﹤0.01%	8945
2023 Q3	–	Sell	-1,505	Closed	-$7.28K	–	9138
2023 Q2	$7.28K	Buy	+1,505	New	+$9.05K	﹤0.01%	8469
2022 Q1	–	Sell	-5,373	Closed	-$257K	–	10799
2021 Q4	$257K	Sell	5,373 -2,330	-30%	-$168K	﹤0.01%	8443
2021 Q3	$714K	Buy	+7,703	New	+$1M	﹤0.01%	6606
2021 Q2	–	Sell	-715	Closed	-$253K	–	10202
2021 Q1	$253K	Buy	+715	New	+$259K	﹤0.01%	7933

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street's NRXP Position: Q2 2026 in Review

Jane Street increased its NRX Pharmaceuticals (NRXP) stake by 170% in Q2 2026, buying an estimated $247K and bringing the position to 119,018 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #8088.

Jane Street first reported a position in NRXP in Q1 2021 and has held it in 9 quarters since. The position peaked at $714K in Q3 2021. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Jane Street held 119,018 shares of NRX Pharmaceuticals worth $487K as of Q2 2026.
Jane Street bought 74,866 NRX Pharmaceuticals shares in Q2 2026, an estimated $247K.
NRX Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8088 holding.
Jane Street first reported a position in NRX Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
Jane Street's NRX Pharmaceuticals position peaked at $714K in Q3 2021.
47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.